vTv Therapeutics (FRA:5VT0) E10: €-22.26 (As of Mar. 2026)


FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
35 GF Score
Price €30.80
GF Value €6,491.15
! 1 Warning Sign
View Full Analysis

What is vTv Therapeutics E10?

vTv Therapeutics FRA:5VT0 +1.32% 35 E10 is €-22.26 as of Mar. 2026. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €6,491.15. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

vTv Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was €1.427. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-22.26 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-26), vTv Therapeutics's current stock price is €30.80. vTv Therapeutics's E10 for the quarter that ended in Mar. 2026 was €-22.26. vTv Therapeutics's Shiller PE Ratio of today is .


vTv Therapeutics  (FRA:5VT0) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


vTv Therapeutics E10 Related Terms


vTv Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics E10 Chart

vTv Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -44.70 -37.75 -23.58

vTv Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.68 -28.13 -26.29 -23.58 -22.26

FRA:5VT0 vs CRDF, GUTS, ACOG: E10 Comparison

For the Biotechnology subindustry, vTv Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Shiller PE Ratio falls into.


FRA:5VT0
35GF Score
vTv Therapeutics Inc FRA:5VT0
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

vTv Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, vTv Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.427/330.2130*330.2130
=1.427

Current CPI (Mar. 2026) = 330.2130.

vTv Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 -16.732 241.018 -22.924
201609 -14.612 241.428 -19.986
201612 -15.926 241.432 -21.782
201703 -16.456 243.801 -22.289
201706 -14.596 244.955 -19.676
201709 -12.753 246.819 -17.062
201712 -14.872 246.524 -19.921
201803 -9.732 249.554 -12.878
201806 -10.614 251.989 -13.909
201809 -2.057 252.439 -2.691
201812 -3.516 251.233 -4.621
201903 -9.204 254.202 -11.956
201906 -3.540 256.143 -4.564
201909 -4.722 256.759 -6.073
201912 -4.680 256.974 -6.014
202003 -3.982 258.115 -5.094
202006 -2.486 257.797 -3.184
202009 -1.019 260.280 -1.293
202012 0.658 260.474 0.834
202103 -2.688 264.877 -3.351
202106 -0.332 271.696 -0.404
202109 -0.680 274.310 -0.819
202112 -3.894 278.802 -4.612
202203 -3.632 287.504 -4.172
202206 -1.514 296.311 -1.687
202209 -2.020 296.808 -2.247
202212 -2.266 296.797 -2.521
202303 -2.017 301.836 -2.207
202306 -2.483 305.109 -2.687
202309 -2.989 307.789 -3.207
202312 -1.531 306.746 -1.648
202403 -1.076 312.332 -1.138
202406 -0.752 314.175 -0.790
202409 -0.793 315.301 -0.831
202412 -0.525 315.605 -0.549
202503 -0.712 319.799 -0.735
202506 -0.798 322.561 -0.817
202509 -0.920 324.800 -0.935
202512 -0.495 324.054 -0.504
202603 1.427 330.213 1.427

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-22.26 mean?
vTv Therapeutics (FRA:5VT0) has a E10 of €-22.26 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on vTv Therapeutics and its competitors.
Is vTv Therapeutics' E10 too high?
vTv Therapeutics' current E10 is €-22.26. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' E10 compare to CRDF and GUTS?
vTv Therapeutics' E10 of €-22.26 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current E10 is €-22.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current E10 of €-22.26. The stock's GF Value™ is €6,491.15, compared to a current price of €30.80 — trading 99.5% below its estimated fair value. The current E10 is €-22.26. vTv Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current E10 is €-22.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €30.80 is trading 99.5% below its estimated GF Value™ of €6,491.15.

Key valuation signals for FRA:5VT0:

  • E10: €-22.26
  • GF Value™: €6,491.15 vs. price of €30.80 (99.5% below fair value)
  • GF Score™: 35/100 with 1 warning sign

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for FRA:5VT0

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.80
Price
€6,491.15
GF Value